Holen Sie sich die Stockscreener-App
20.48
1.34%
-0.365
Handel nachbörslich:
20.62
0.145
+0.71%
Schlusskurs vom Vortag:
$20.84
Offen:
$20.84
24-Stunden-Volumen:
82,458
Relative Volume:
0.87
Marktkapitalisierung:
$691.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.02%
1M Leistung:
-12.59%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$19.45
$21.61
1-Wochen-Bereich:
$19.45
$23.61
52-Wochen-Spanne:
$19.45
$30.56
Spyglass Pharma Inc Stock (SGP) Company Profile
Firmenname
Spyglass Pharma Inc
Sektor
Branche
Telefon
949-284-6904
Adresse
27081 ALISO CREEK ROAD, ALISO VIEJO
Compare SGP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
20.67 | 696.75M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-03-03 | Eingeleitet | Citigroup | Buy |
| 2026-03-03 | Eingeleitet | Jefferies | Buy |
| 2026-03-03 | Eingeleitet | Leerink Partners | Outperform |
| 2026-03-03 | Eingeleitet | Stifel | Buy |
Spyglass Pharma Inc Aktie (SGP) Neueste Nachrichten
Spyglass Pharma (SGP) Stock Chart and Price History 2026 $SGP - MarketBeat
SpyGlass Pharma to Participate in Upcoming Investor Conferences - The Manila Times
SpyGlass Pharma execs set for three June healthcare investor events - Stock Titan
SpyGlass Pharma: New add-on CPT code supports BIM-IOL System - Eyes On Eyecare
SpyGlass Secures Billing Code for IOL Platform - Orange County Business Journal
Spyglass Pharma IncBIM-Iol System Phase 3 Trial Enrollment Expected To Complete In 2027 - TradingView
Eye surgeons get new code for implant treating glaucoma during cataract surgery - Stock Titan
Spyglass Pharma (SGP) Earnings Date and Reports 2026 $SGP - MarketBeat
SpyGlass Pharma (SGP) Q1 2026 Earnings Miss by Significant: Key TakeawaysBuyback Authorization - newser.com
SpyGlass Pharma posts Q1 loss as Phase 3 trials advance By Investing.com - Investing.com South Africa
SpyGlass Pharma posts Q1 loss as Phase 3 trials advance - Investing.com India
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Sahm
Number of shareholders of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
SpyGlass Pharma (SGP) boosts cash to $251M after IPO while losses widen - Stock Titan
SpyGlass Pharma (SGP) boosts cash with IPO and reports strong BIM-IOL glaucoma data - Stock Titan
SpyGlass Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Spyglass Pharma (SGP) Institutional Ownership 2026 $SGP - MarketBeat
Eye implant ended IOP-lowering drops for 98% in trial - Stock Titan
SGP SpyGlass Pharma reports solid late-stage trial progress, lays out aggressive commercial expansion plans for 2025.Stock Community Signals - newser.com
What fair value gap SpyGlass Pharma (SGP)? (Buying Pressure) 2026-05-01Verified Stock Signals - Newser
SGP Ownership | SPYGLASS PHARMA INC (NASDAQ:SGP) - ChartMill
Eye care firm SpyGlass Pharma soars 65% in trading debut - MSN
SGP Technical Analysis | Trend, Signals & Chart Patterns | SPYGLASS PHARMA INC (NASDAQ:SGP) - ChartMill
All News for SGP : SpyGlass Pharma, Inc. - Zacks Investment Research
Dividend HistorySpyGlass Pharma, Inc. (SGP) - Zacks Investment Research
Is SpyGlass Pharma (SGP) Stock Good for Long Term | Price at $22.30, Down 0.71%Social Buy Zones - Newser
SpyGlass Pharma, Inc.: Fundamental Analysis and Financial Ratings | SGP | US85220G1094 - marketscreener.com
SGP: SpyGlass Pharma, Inc.Insider Transations - Zacks Investment Research
SpyGlass Pharma, Inc. (SGP) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
SpyGlass Pharma Reports Fourth Quarter and Full-Year 2025 Results - VisionMonday.com
SpyGlass Pharma, Inc. (SGP) stock price, news, quote and history - Yahoo Finance UK
Stifel reiterates Buy on SpyGlass Pharma stock, $42 target By Investing.com - Investing.com Canada
Stifel reiterates Buy on SpyGlass Pharma stock, $42 target - Investing.com
SpyGlass Pharma’s BIM-IOL System: Transforming Glaucoma and Ocular Hypertension Treatment with Long-Acting Drug Delivery Solutions - Minichart
SpyGlass Pharma (NASDAQ: SGP) outlines long-acting glaucoma implant pipeline - Stock Titan
[8-K] SpyGlass Pharma, Inc. Reports Material Event - Stock Titan
97% stopped glaucoma drops in SpyGlass eye implant study - Stock Titan
New Glaucoma Treatment Uses Eye Implant for Three-Year Drug Delivery - University of Colorado Anschutz
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to S&P TMI Index - marketscreener.com
SGP Stock Price, News & Analysis - Stock Titan
SpyGlass Valued at $900M After IPO - Orange County Business Journal
Spyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - MarketBeat
Spyglass Pharma (NASDAQ:SGP) Coverage Initiated by Analysts at HC Wainwright - Defense World
H.C. Wainwright initiates SpyGlass Pharma stock coverage with buy rating By Investing.com - Investing.com Canada
SpyGlass Pharma reports positive 12-month Phase 1/2 BIM-IOL results with high drop-free rates - TradingView
SpyGlass Pharma reports positive 12-month glaucoma device trial data - Investing.com Australia
Finanzdaten der Spyglass Pharma Inc-Aktie (SGP)
Es liegen keine Finanzdaten für Spyglass Pharma Inc (SGP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Spyglass Pharma Inc-Aktie (SGP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Behbahani Ali | Director |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Florence Anthony A. Jr. | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| BASKETT FOREST | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| New Enterprise Associates 17, | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Yang Rick | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Makhzoumi Mohamad | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| SANDELL SCOTT D | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Chang Carmen | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Walker Paul Edward | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Mathers Edward T | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):